씨포테라퓨틱스(CCCC)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $3.39 (-0.73%), 시가총액 $0.39B, 52주 최저~최고 $1.25 ~ $3.68.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaboration
씨포테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
씨포테라퓨틱스의 현재 주가는 $3.39 (-0.73%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
씨포테라퓨틱스의 시가총액은 약 $0.39B입니다.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioav